請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20887
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 沈立言(Lee-Yan Sheen) | |
dc.contributor.author | Yi-Chee Ng | en |
dc.contributor.author | 黃熠埼 | zh_TW |
dc.date.accessioned | 2021-06-08T03:08:37Z | - |
dc.date.copyright | 2020-08-24 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-08-19 | |
dc.identifier.citation | Al-Obaide, M.A.I., Singh, R., Datta, P., Rewers-Felkins, K.A., Salguero, M.V., Al-Obaidi, I., Kottapalli, K.R., Vasylyeva, T.L. Gut microbiota-dependent trimethylamine-N-oxide and serum biomarkers in patients with T2DM and advanced CKD. Journal of Clinical Medicine 6, 86 (2017). Aldana-Hernández, P., Leonard, K.A., Zhan, Y.Y., Curtis, J.M., Field, C.J., Jacobs, R.L. Dietary choline or trimethylamine N-oxide supplementation does not influence atherosclerosis development in Ldlr-/- and Apoe-/- male mice. The Journal of Nutrition 150(2), 249-255 (2019). Ascher, S., Reinhardt, C. The gut microbiota: an emerging risk factor for cardiovascular and cerebrovascular disease. European Journal of Immunology 48(4), 564-575 (2017) Bennett, B.J., de Aguiar Vallim, T.Q., Wang, Z., Shih, D.M., Meng, Y., Gregory, J., Allayee, H., Lee, R., Graham, M., Crooke, R., Edwards, P.A., Hazen, S.L., Lusis, A.J. Trimethylamine-N-Oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metabolism 17(1), 49-60 (2013). Bernstein, A.M., Sun, Q., Hu, F.B., Stampfer, M.J., Manson, J.E., Willet, W.C. Major dietary protein sources and the risk of coronary heart disease in women. Circulation 122(9), 876-883(2010). Bibbins-Domingo, K., Chertow, G.M., Coxson, P.G., Moran, A., Lightwood, J.M., Pletcher, M.J., Goldman, L. Projected effect of dietary salt reductions on future cardiovascular disease. The New England Journal of Medicine 326(7), 590-599 (2010). Bremer, J., Carnitine – metabolism and functions. Physiological Reviews 63(4), 1420-1480 (1983). Boini, K.M., Hussain, T., Li, P.L., Koka, S. Trimethylamine-N-Oxide instigates NLRP3 inflammasome activation and endothelial dysfunction. Cellular Physiology and Biochemistry 44(1), 152-162 (2017). Calderón-Pérez, L., Gosalbes, M.J., Yuste, S., Valls, R.M., Pedret, A., Llauradó, E., Jimenez-Hernandez, N., Artacho, A., Pla-Pagà, L., Companys, J., Ludwig, I., Romero, M., Rubió, L., Solà, R. Gut metagenomics and short chain fatty acids signature in hypertension: a cross-sectional study. Scientific Reports 10(1), 6436 (2020). Campo, A.M., Bodea, S., Hamer, H.A., Marks, J.A., Haiser, H.J., Turnbaugh, P.J., Balskus, E.P. Characterization and detection of a widely distributed gene cluster that predicts anaerobic choline utilization by human gut bacteria. mBio 6(2), e00042-15 (2015). Chen, M.L., Yi, L., Zhang, Y., Zhou, X., Ran, L., Yang, J., Zhu, J.D., Zhang, Q.Y., Mi, M.T. Resveratrol attenuates trimethylamine-N-oxide (TMAO)-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodelling of the gut microbiota. mBio 7(2), e02210-e02215 (2016). Chingnard, M., Le Couedic, J.P., Tence, M., Vargaftig, B.B., Benveniste, J. The role of platelet-activating factor in platelet aggregation. Nature 279(5716), 799-800 (1979). Collins, H.L., Drazul-Schrader, D., Sulpizio, A.C., Koster, P.D., Williamson, Y., Adelman, S.J., Owen, K., Sanli, T., Bellamine, A. L-carnitine intake and high trimethylamine N –oxide plasma levels correlate with low aortic lesions in Apoe(-/-) transgenic mice expressing CETP. Atherosclerosis 244, 29-37 (2016). Eckburg, P.B., Bik, E.M., Bernstein, C.N., Purdom, E., Dethlefsen, L., Sargent, M., Gill, S.R., Nelson, K.E., Relman, D.A. Diversity of the human intestinal microbial flora. Science 308(5728), 1635-1638 (2005). Ference, B.A., Ginsberg, N.H., Graham, I., Ray, K.K., Packard, C.J., Bruckert, E., Hegele, R.A., Krauss, R.M., Raal, F.J., Schunkert, H., Watts, G.F., Borén, J., Fazio, S., Horton, J.D., Masana, L., Nicholls, S.J., Nordestgaard, B.G., van de Sluis, B., Taskinen, M.R., Tokgözoglu, L., Landmesser, U., Laufs, U., Wiklund, O., Stock, J.K., Chapman, M.J., Catapano, A.L. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. European Heart Journal 38(32), 2459-2472 (2017). Falony, G., Vieira-Silva, S., Raes, J. Microbiology meets big data: the case of gut microbiota-derived trimethylamine. Annual Review of Microbiology 69, 305-321 (2015). Fennema, D., Philips, I.R., Stephard, E.A. Trimethylamine and Trimethylamine N-Oxide, a Flavin-containing monooxygenase 3 (FMO3)-mediated host-microbiome metabolic axis implicated in health and disease. Drug Metabolism and Disposition 44(11), 1839-1850 (2016). Garcia, M., Mulvagh, S.L., Merz, C.N.B., Buring, J.E., Manson, J.E. Cardiovascular disease in women. Circulation Research 118(8), 1273-1293 (2016). Geng, J., Yang, C., Wang, B., Zhang, X., Hu, T., Gu, Y., Li, J. Trimethylamine N-Oxide promotes atherosclerosis via CD36-dependent MAPK/JNK pathway. Biomedicine Pharmacotherapy 97, 941-947 (2018). Heianza. Y., Ma, W., Manson, J.E., Rexrode, K.M., Qi, L. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: a systematic review and meta-analysis of prospective studies. Journal of the American Heart Association 6(7), e004947 (2017). Janeiro, M.H., Ramírez, M.J., Milagro, F.I., Martínez, J.A., Solas, M. Implication of trimethylamine N-oxide (TMAO) in disease: potential biomarker or new therapeutic target. Nutrients 10(10), 1398 (2018). Jie, Z., Xia, H., Zhong, S.L., Feng, Q., Li, S., Liang, S., Zhong, H., Liu, Z., Gao, Y., Zhao, H., Zhang, D., Su, Z., Fang, Z., Lan, Z., Li, J., Xiao, L., Li, J., Li, R., Li, X., Li, F., Ren, H., Huang, Y., Peng, Y., Li, G., Wen, B., Dong, B., Chen, J.Y., Geng, Q.S., Zhang, Z.W., Yang, H., Wang, J., Wang, J., Zhang, X., Madsen, L., Brix, S., Ning, G., Xu, X., Liu, X., Hou, Y., Jia, H., He, K., Kristiansen, K. The gut microbiome in atherosclerotic cardiovascular disease. Nature Communications 8, 845 (2017). Jin, M., Qian, Z., Yin, J., Xu, W., Zhou, X. The role of intestinal microbiota in cardiovascular disease. Journal of Cellular and Molecular Medicine 23(4), 2343-2350 (2019). Jonsson, A.L., Bäckhed, F. Role of gut microbiota in atherosclerosis. Nature Reviews Cardiology 14(2), 79-87 (2017). Jonsson, A.L., Caesar, R., Akrami, R., Reinhardt, C., Hållenius, F.F., Borén, J., Bäckhed, F. Impact of gut microbiota and diet on the development of atherosclerosis in Apoe-/- mice. Atherosclerosis, Thrombosis, and Vascular Biology 38(10), 2318-2326 (2018). Koeth, R.A., Wang, Z., Levison, B.S., Buffa, J.A., Org, E., Sheehy, B.T., Britt, E.B., Fu, X., Wu, Y., Li, L., Smith, J.D., DiDonato, J.A., Chen, J., Li, H., Wu, G.D., Lewis, J.D., Warrier, M., Brown, J.M., Krauss, R.M., Tang, W.H.W., Bushman, F.D., Lusis, A.J., Hazen, S.L. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature Medicine 19(5), 576-585 (2013). Koeth, R.A., Levison, B.S., Culley, M.K., Buffa, J.A., Wang, Z., Gregory, J.C., Org, E., Wu, Y., Li, L., Smith, J.D., Tang, W.H.W., DiDonato, J.A., Lusis, A.J., Hazen, S.L. γ–Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metabolism 20(5), 799-812 (2014). Koeth, R.A., Lam-Galvez, B.R., Kirsop, J., Wang, Z., Levison, B.S., Gu, X., Copeland, M.F., Bartlett, D., Cody, D.B., Dai, H.J., Culley, M.K., Li, X.S., Fu, X., Wu, Y., LI, L., DiDonato, J.A., Tang, W.H.W., Garcia-Garcia, J.C., Hazen, S.L. L-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. The Journal of Clinical Investigation 129(1), 373-387 (2019). Liu, Y., Dai, M. Trimethylamine N-oxide generated by the gut microbiota is associated with vascular inflammation: new insights into atherosclerosis. Mediators of Inflammation, doi: 10.1155/2020/4634172. (2020) Lusis, A.J. Atherosclerosis. Nature 407(6801), 233-241 (2000). Menni, C., Lin, C., Cecelja, M., Mangino, M., Matey-Hernandez, M.L., Keehn, L., Mohney, R.P., Steves, J., Spector, T.D., Kuo, C.F., Chowienczyk, P., Valdes, A.M. Gut microbial diversity is associated with lower arterial stiffness in women. European Heart Journal 39(25), 2390-2397 (2018). Micha, R., Wallace, S.K., Mozaffarian, D. Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis. Circulation 122(21), 2271-2283 (2010). Pepine, C.J. The effects of angiotensin-converting enzyme inhibition on endothelial dysfunction: potential role in myocardial ischemia. The Americal Journal of Cardiology 82(9), 23S-27S (1998). Qiu, L., Yang, D., Tao, X., Yu, J., Xiong, H., Wei, H. Enterobacter aerogenes ZDY01 attenuates choline-induced trimethylamine N-oxide levels by remodeling gut microbiota in mice. Journal of Microbiology and Biotechnology 27(8), 1491-1499 (2017). Qiu, L., Tao, X., Xiong, H., Yu, J., Wei, H. Lactobacillus plantarum ZDY04 exhibits a strain-specific property of lowering TMAO via the modulation of gut microbiota in mice. Food Function 9(8), 4299-4309 (2018). Repáraz, J.O., Kasper, L.H. The second brain: is the gut microbiota a link between obesity and central nervous system disorders? Current Obesity Reports 5(1), 51-64 (2016). Romano, K.A., Vivas, E.I., Amador-Noguez, D., Rey, F.E. Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. mBio 6(2), e02481-14 (2015). Ross, R., Glomset, J.A. Atherosclerosis and the arterial smooth muscle cell. Science 180(4093), 1332-1339 (1973). Schuijt, T.J., Lankelma, J.M., Scicluna, B.P., Melo, F.S.e., Roelofs, J.J., Boer, J.D., Hoogendijk, A.J., Beer, R., Vos, A., Belzer, C., Vos, W.M., Poll, T., Wiersinga, W.J. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. Gut 65(4), 575-583 (2016). Sekirov, I., Russell, S.L., Antunes, L.C., Finlay, B.B. Gut microbiota in health and disease. Physiological Review 90, 859-904 (2010). Siri-Tarino, P.W., Sun, Q., Hu, F.B., Krauss, R.M. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. The American Journal of Clinical Nutrition 91(3), 535-546 (2010). Slack, J. Risk of ischaemic heart-disease in familial hyperlipoproteinaemic states. The Lancet 294(7635), 1380-1382 (1969). Smith, D.D., Tan, X., Tawfik, O., Milne, G., Stechschulte, D.J., Dileepan, K.N. Increased aortic atherosclerotic plaque development in female apoliprotein E-null mice is associated with elevated thromboxane A2 and decreased prostacyclin production. Journal of Physiology and Pharmacology 61(3), 309-316 (2010). Stepankova, R., Tonar, Z., Bartova, J., Nedorost, L., Rossman, P., Poledne, R., Schwarner, M., Tlaskalova-Hogenova, H. Absence of microbiota (germ-free conditions) accelerates the atherosclerosis in ApoE-deficient mice fed standard low cholesterol diet. Journal of Atherosclerosis and Thrombosis 17(8), 796-804 (2010). Tang, W.H.W., Wang, Z., Levison, B.S., Koeth, R.A., Britt, E.B., Fu, X., Wu, Y., Hazen, S.L. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. The New England Journal of Medicine 368(17), 1575-1584 (2013). Tilg, H. A gut feeling about thrombosis. The New England Journal of Medicine 374(25), 2494-2496 (2016). Wang, Z., Zhao, Y. Gut microbiota derived metabolites in cardiovascular health and disease. Protein Cell 9(5), 416-431 (2018). Wang, Z., Klipfell, E., Bennett, B.J., Koeth, R.A., Levison, B.S., DuGar, B., Feldstein, A.E., Britt, E.B., Fu, X., Chung, Y.M., Wu, Y., Schauer, P., Smith, J.D., Allayee, H., Tang, W.H.W., DiDonato, J.A., Lusis, A.J., Hazen, S.L. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472(7341), 57-63 (2011). Wang, Z., Koeth, R.A., Buffa, J.A., Levison, B.S., Zhu, W., Org, E., Gu, X., Huang, Y., Zamanian-Daryoush, M., Culley, M.K., DiDonato, A.J., Fu, X., Hazen, J.E., Krajcik, D., DiDonato, J.A., Lusis, A.J., Hazen, S.L. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163(7), 1585-1595 (2015). Wang, Z., Bergeron, N., Levison, B.S., Li, X.S., Chiu, S., Jia, X., Koeth, R.A., Lin, L., Wu, Y., Tang, W.H.W., Krauss, R.M., Hazen, S.L. Impact of chronic dietary red meat, white meat, or non-meat protein on trimethylamine-N-oxide metabolism and renal excretion in healthy men and women. European Heart Journal 40(7), 583-594 (2018). Wu, W.K., Panyod, S., Ho, C.T., Kuo, C.H., Wu, M.S., Sheen, L.Y. Dietary allicin reduces transformation of L-carnitine to TMAO through impact on gut microbiota. Journal of Functional Foods 15, 408-417 (2015). Wu, W.K., Chen, C.C., Liu, P.Y., Panyod, S., Liao, B.Y., Chen, P.C., Kao, H.L., Kuo, H.C., Kuo, C.H., Chiu, T.H.T., Chen, R.A., Chuang, H.L., Huang, Y.T., Zou, H.B., Hsu, C.C., Chang, T.Y., Lin, C.L., Ho, C.T., Yu, H.T., Sheen, L.Y., Wu, M.S. Identification of TMAO-producer phenotype and host-diet-gut dysbiosis by carnitine challenge test in human and germ-free mice. Gut 68(8), 1439-1449 (2019). Yazdanyar, A., Newman, A.B. The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. Clinics in Geriatric Medicine 25(4), 563-577 (2009). Zhang, J., Song, L., Wang, Y., Liu, C., Zhang, L., Zhu, S., Liu, S., Duan, L. Beneficial effect of butyrate-producing Lachnospiraceae on stress-induced visceral hypersensitivity in rats. Journal of Gastroenterology and Hepatology 34(8), 1368-1376 (2019). Zhu, W., Gregory, J.C., Org, E., Buffa, J.A., Gupta, N., Wang, Z., Li, L., Fu, X., Wu, Y., Mehrabian, M., Sartor, R.B., Mclntyre, T.M., Silverstein, R.L., Tang, W.H.W., DiDonato, J.A., Brown, J.M., Lusis, A.J., Hazen, S.L. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 165(1), 111-124 (2016). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20887 | - |
dc.description.abstract | 根據世界衛生組織 (World Health Organization, WHO) 最新的統計,心血管疾病 (Cardiovascular disease, CVD) 是全球人口死亡的主要原因。而根據台灣衛生福利部所公佈的 108 年國人十大死亡原因中,心血管相關疾病所造成的死亡總人數已超過位於榜首的癌症,可見預防 CVD 之必要性。隨著近年來腸道菌相相關研究的興起,腸道菌及其代謝產物如氧化三甲胺 (Trimethylamine-N-oxide) 、短鏈脂肪酸 (Short chain fatty acids, SCFA) 等被證實與 CVD 的發生有關。其中,腸道菌透過生成 TMAO 導致人類 CVD 的發現是目前科學理論架構完整且最具臨床應用價值之一的研究方向。許多研究指出動脈粥狀硬化 (Atherosclerosis) 是造成 CVD 的主要原因,並證實 TMAO 具有致動脈粥狀硬化 (Pro-atherogenic) 及血栓形成的能力,因此人體血液中 TMAO 的濃度是促使動脈粥狀硬化的重要且獨立的危險因子。TMAO 的產生主要來自於飲食中的肉類及蛋類所含的肉鹼 (Carnitine) 和膽鹼 (Choline),在腸道中被腸道菌代謝利用並透過肝臟酵素氧化而形成 TMAO。動脈粥狀硬化是一種慢性發炎性疾病,低密度脂蛋白 (Low-density lipoprotein, LDL) 氧化後具有細胞毒性,會引起血管內皮發生發炎反應,最終導致動脈粥狀硬化斑塊的生成而逐漸阻塞動脈。因此,減輕發炎反應可以有效降低主動脈斑塊的生成。黃豆經過發酵會產生黃酮類 (Flavones)、異黃酮 (Isoflavones)、黃頑酮類 (Flavanones) 等,這些化合物具有許多生理活性如抗發炎、抗氧化、抗過敏等活性。此外,根據本實驗室初步 in vitro study 結果發現,黃豆發酵萃取物可以有效抑制特定菌株的生長,進而抑制 carnitine 及 choline 轉換成 TMA子路徑。於短期 C57BL/6J 小鼠實驗中也發現黃豆發酵萃取物的介入可顯著降低小鼠血液中 TMA 及 TMAO 的濃度,減緩血小板凝集的發生。然而,前述 C57BL/6J 小鼠模式無法提供動脈粥狀硬化的主要表徵,如主動脈斑塊的生成。因此,本實驗將該用 Apoe-/- 小鼠動物模式探討黃豆發酵萃取物是否能透過調節小鼠腸道菌相,降低 TMAO 的產生,進而減少小鼠主動脈斑塊的生成,達到心血管保護的效果。實驗結果顯示, 黃豆發酵萃取物可顯著降低 carnitine 介入後小鼠血液中 TMAO 的濃度,進而減少血管斑塊之生成,同時降低了小鼠血液中 TG 的濃度。此外,黃豆發酵萃取物也改善了 choline 介入下小鼠的肝功能指數並提升了小鼠血液中高密度脂蛋白 (HDL-C) 的濃度。根據小鼠菌相分析的結果顯示,黃豆發酵萃取物顯著改變 carnitine 組別小鼠整體腸道菌相的組成,且提高腸道菌之多樣性及豐富度。而主座標分析 (PCoA) 結果顯示黃豆發酵萃取物不會改變給予 choline 的小鼠整體腸道菌相之組成,但對於特定菌群的相對豐富度仍造成顯著的改變。綜上所述,黃豆發酵萃取物可透過改善血脂及肝功能,調節腸道菌相,降低 TMAO 的產生,進而減少主動脈斑塊的生成,達到心血管保護之功效。 | zh_TW |
dc.description.abstract | According to the statistic announced by the World Health Organization (WHO) in 2018, the cardiovascular disease (CVD) is the main cause of death worldwide and have remained the leading causes of death globally. For the prevalence in Taiwan, Ministry of Health and Welfare (MOHW) stated that the mortality of CVD-related diseases is comparable to those of cancer. Thus, the prevention of CVD is increasingly important as CVD is considered as the health burden worldwide. Atherosclerosis is the main underlying cause of CVD and TMAO plasma levels have been proved to be associated with atherosclerosis. Studies recently have identified TMAO as an essential proatherogenic and prothrombotic compound that contribute to the progression of atherosclerosis. Studies have proved that the specific diet-gut microbiota interaction plays a critical role in the CVD pathogenesis. TMAO is produced mainly from the gut microbiota-dependent metabolism of dietary carnitine and choline. L-carnitine and choline, the abundant nutrient in red meat, eggs and milk, are hydrolysed and are converted to trimethylamine (TMA) by microbial lyases in the colon. TMA is carried via the portal circulation to the liver where it is rapidly converted by host hepatic flavin-containing monooxygenases (FMO3) into trimethylamine N-oxide (TMAO). Therefore, modification of gut microbiota may contribute to the reduced formation of serum TMAO. The main compounds identified in fermented soybean products were flavanons, isoflavones and flavonols, which possess many biological activities such as anti-inflammatory, antioxidant and anti-allergy. Our laboratory previous in vitro study showed that the fermented soybean extracts inhibited the growth of specific bacteria responsible for the transformation of choline and carnitine into TMA and further reduced the production of serum TMAO. Besides, the fermented soybean extracts prevented the elevation of serum TMAO from carnitine and choline diet in a short-term C57BL/6J mice model and resulted in decreased platelet aggregation. Therefore, my present study aimed to investigate the cardiovascular protective effect of the fermented soybean extract against the formation of aortic lesions and CVD-related biomarkers by using Apoe-/- mice. The result showed that the fermented soybean product significantly reduced the concentration of serum TMAO and triglyceride (TG), and the formation of aortic lesions in mice fed with carnitine diet. Furthermore, fermented soybean extracts decreased the serum AST and ALT, and increased the serum HDL-C in mice fed with choline diet. Gut microbiota analysis of carnitine-fed mice showed that the fermented soybean extracts significantly altered the overall gut microbiota composition and increased the diversity and richness of gut microbiota. The PCoA showed no significant differences of overall gut microbiota composition after consuming fermented soybean extracts in choline-fed mice. However, the relative abundance of specific gut bacteria such as Erysipelatoclostridium and Coprococcus 2 in genus level decreased significantly after fermented soybean extracts intervention. In, conclusion, intervention of fermented soybean extracts exhibited cardio-protective effects by reducing the production of serum TMAO and formation of aortic lesion, improving the serum biochemical through modulation of gut microbiota. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T03:08:37Z (GMT). No. of bitstreams: 1 U0001-1808202022234000.pdf: 4323807 bytes, checksum: 7a2261b9d31d69bbaafe7975e39d4680 (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 目錄
中文摘要………………………………………………………………………………... I Abstract ……………………………………………………………………...…….….. III 目錄……………………………………………………………………………………. V 圖次…………………………………………………………………………….…… VIII 表次…………………………………………………………………………………… .X 縮寫表………………………………………………………………………………... XI 第一章 前言……………………………………………………………………………. 1 第二章 文獻回顧………………………………………………………………………. 3 第一節 心血管疾病……………………………………………………………. 3 一、心血管疾病之流行病學………………………………………….. 3 二、心血管疾病之危險因子……………………………..…………… 3 三、動脈粥狀硬化………………………………………………..…… 5 第二節 腸道菌相……………………………………………………………… 7 一、腸道菌相在人體扮演的角色 …………………………………… 7 二、腸道菌與動脈粥狀硬化 ………………………………………… 7 三、飲食、腸道菌與心血管疾病之因果關係 ……………………… 8 第三節 氧化三甲胺 ………………………………………………………… 11 一、氧化三甲胺之生成 …………………………………...………… 11 二、氧化三甲胺與心血管疾病之關係 ………………………..…… 12 第四節 黃豆發酵萃取物 …………………………………………………… 15 一、黃豆及黃豆發酵食品 ……………………..…………………… 15 二、黃豆發酵萃取物之簡介 …………………………...…………… 15 第三章 研究假說與目的 ……………………………………………..……………… 17 第一節 研究假說 ……………………………………………..……………… 17 第二節 研究目的 ……………………………………………..……………… 17 第四章 實驗架構 …………………………………..……………………..………… 18 第五章 實驗材料與方法 …………………………………..……………………..… 20 第一節 實驗材料 …………………………………..……………………..… 20 一、黃豆發酵萃取物 …………………………..………………..….. 20 二、實驗藥品 ………………………..……..……………………..… 20 三、實驗設備及儀器 …………………………………..…………… 21 第二節 實驗方法 …………………………………..……………………..… 23 一、黃豆發酵萃取物之劑量設計及製備 …………………....…….. 23 二. 動物實驗 ………………………..……..……………………..… 23 第三節 統計分析 ………………………………………………………..….. 28 第六章 實驗結果 …………………………………..………………..……………..… 29 第一節 主動脈斑塊之定量分析………………...…………..……………..… 29 第二節 標靶代謝體學分析 ………………...…………..………………….… 29 第三節 血清生化分析 ………………...…………..……………………….… 30 第四節 菌相分析 ………………...…………..…………………...………..… 30 一、α 多樣性 ………………...…………..…………….....………..… 30 二、β 多樣性 ………………...…..…………………...………..…..… 30 三、菌相相對豐富度 ………………...…………..……………….… 31 第五節 組織病理切片分析 ………………...…………………...………..… 32 第七章 實驗討論 ……………………...…………..…………………...………..….. 33 第八章 實驗結論 ………………...…………..……………..…………...………..… 39 第九章 未來研究方向 ………………...…………..…………………...………....… 41 第十章 實驗結果圖表 ……………….....…………..…………………...………..… 42 第十一章 參考文獻 ………………...…………..…………………...…………....… 60 | |
dc.language.iso | zh-TW | |
dc.title | 探討黃豆發酵萃取物對於 Apoe−/− 小鼠腸道菌相的影響與心血管疾病的關聯性 | zh_TW |
dc.title | Investigation of fermented soybean extract on cardiovascular disease through gut microbiota in Apoe−/− mice | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 吳明賢(Ming-Shiang Wu),莊曉莉(Hsiao-Li Chuang) | |
dc.subject.keyword | 心血管疾病,氧化三甲胺,肉鹼,膽鹼,腸道菌相,黃豆發酵萃取物, | zh_TW |
dc.subject.keyword | CVD,TMAO,carnitine,choline,gut microbiota,fermented soybean extract, | en |
dc.relation.page | 65 | |
dc.identifier.doi | 10.6342/NTU202004039 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2020-08-20 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 食品科技研究所 | zh_TW |
顯示於系所單位: | 食品科技研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1808202022234000.pdf 目前未授權公開取用 | 4.22 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。